therapeutics

Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis
Koichi Takeda, Noriko Yanagitani

Annals of the Rheumatic Diseases May 2022, annrheumdis-2022-222628; DOI: 10.1136/annrheumdis-2022-222628
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee

Annals of the Rheumatic Diseases Jun 2022, 81 (6) 815-822; DOI: 10.1136/annrheumdis-2021-221664
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
Matthew J Koster, Cynthia S Crowson, Rachel E Giblon, Jane M Jaquith, Ali Duarte-García, Eric L Matteson, Cornelia M Weyand, Kenneth J Warrington

Annals of the Rheumatic Diseases Jun 2022, 81 (6) 861-867; DOI: 10.1136/annrheumdis-2021-221961
Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis
Cristina Valero, Juan Pablo Baldivieso, Isidoro Gonzalez-Alvaro, Eva Tomero, Santos Castañeda, Rosario García-Vicuña

Annals of the Rheumatic Diseases Jun 2022, 81 (6) 899-901; DOI: 10.1136/annrheumdis-2021-221812
SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection
Enrique Morales, Maria Galindo

Annals of the Rheumatic Diseases May 2022, annrheumdis-2022-222512; DOI: 10.1136/annrheumdis-2022-222512
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7
Haiyan Zhang, Yan Shao, Zihao Yao, Liangliang Liu, Hongbo Zhang, Jianbin Yin, Haoyu Xie, Kai Li, Pinglin Lai, Hua Zeng, Guozhi Xiao, Chun Zeng, Daozhang Cai, Xiaochun Bai

Annals of the Rheumatic Diseases May 2022, 81 (5) 676-686; DOI: 10.1136/annrheumdis-2021-221513
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
Ana Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Henrique Carriço da Silva, Carla G S Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Carlo Scognamiglio Renner Araujo, Tatiane Lie Nakai, Clóvis Artur Silva, Tatiana Pedrosa, Léonard de Vinci Kanda Kupa, Matheus Santos Rodrigues Silva, Guilherme Guimarães Moreira Balbi, Esper Georges Kallas, Nádia Emi Aikawa, Eloisa Bonfa

Annals of the Rheumatic Diseases May 2022, 81 (5) 710-719; DOI: 10.1136/annrheumdis-2021-221735
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
Atul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester

Annals of the Rheumatic Diseases Apr 2022, annrheumdis-2021-222027; DOI: 10.1136/annrheumdis-2021-222027
Pilot study of baricitinib for active Sjogren’s syndrome
Wei Bai, Huilan Liu, Lei Dou, YunJiao Yang, XiaoMei Leng, Mengtao Li, Wen Zhang, Yan Zhao, Xiaofeng Zeng

Annals of the Rheumatic Diseases Mar 2022, annrheumdis-2021-222053; DOI: 10.1136/annrheumdis-2021-222053
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala

Annals of the Rheumatic Diseases Mar 2022, annrheumdis-2021-221425; DOI: 10.1136/annrheumdis-2021-221425

Main menu

therapeutics

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

therapeutics

Pages